Bordetella holmesii isolated from a patient with sickle cell anemia: analysis and comparison with other Bordetella holmesii isolates  by Njamkepo, E. et al.
ORIGINAL ARTICLE
Bordetella holmesii isolated from a patient with sickle cell anemia:
analysis and comparison with other Bordetella holmesii isolates
E. Njamkepo1, F. Delisle2, I. Hagege3, G. Gerbaud4 and N. Guiso1
1Laboratoire des Bordetella, Centre National de Re´fe´rence des Bordetella, Institut Pasteur, 2Laboratoire de Bacte´riologie, Hoˆpital
Tenon, and 3Hopital de Jour de Me´decine, Hoˆpital Tenon, 4Unite´ des Agents Anti-Bacte´riens, Centre National de Re´fe´rence des
Antibiotiques, Institut Pasteur, Paris, France
Objective To analyze a Bordetella holmesii isolate from a patient with sickle cell anemia and to compare it with
other B. holmesii strains and isolates and with strains of B. pertussis and B. bronchiseptica, two well-characterized
species of the Bordetella genus.
Methods The bacteriological characteristics and proteins produced by the B. holmesii isolate and the reference
strain (ATCC 51541) were analyzed and compared with those of B. pertussis and B. bronchiseptica using sera
from patients infected with B. pertussis, B. bronchiseptica or B. holmesii.
Results The bacteriological characteristics of the B. holmesii isolate studied here were similar to those of the
B. holmesii reference strain and other isolates. Some of the proteins produced by B. holmesii isolates were similar
to those produced by B. pertussis and B. bronchiseptica, but none of these proteins was similar to the toxins and
adhesins involved in the pathogenicity of B. pertussis and B. bronchiseptica. The phenotypic diversity of the
proteins produced by B. holmesii isolates and the reference strain was striking.
Conclusions Our results suggest that either, the expression of B. holmesii proteins is regulated as in B. pertussis
and B. bronchiseptica, with the B. holmesii strain exhibiting different phases, or the proteins produced in B.
holmesii are different.
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INTRODUCTION
The Bordetella genus includes seven species, the last of which
was discovered in 1996. Most of these species are responsible
for respiratory infections.B. pertussis, a strictly human pathogen,
and B. parapertussis, a pathogen in both humans and sheep, are
agents of whooping cough [1], B. bronchiseptica is a respiratory
pathogen in many animal species, including dogs, pigs, rabbits
and cats, but may also cause pneumonia and bacteremia in
humans [2,3], B. avium causes respiratory infections in poultry
but has rarely been reported to cause infections in humans [4],
and B. hinzii is a respiratory disease agent in poultry; only
three cases of human infections with this bacterium have been
described [5–7]. The other two species, B. holmesii and
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B. trematum, are not primarily associated with respiratory infec-
tions. B. trematum has been isolated from ear infections and
wounds in humans, and its role as a pathogen is not known [8].
B. holmesii has been isolated from young adults with septicemia
[9,10]. B. holmesiiwas originally described as CDC nonoxidizer
group 2 (NO-2) isolates collected from blood cultures, usually
from young adults, mostly with underlying disorders. B. holmesii
has also been isolated from asplenic patients [10,11]. However,
it has been reported that B. holmesii can also be isolated from
sputum and may colonize the respiratory tract like other Bor-
detella species [10]. The reservoir of this bacterium is unknown.
We present the ﬁrst clinical description in France of an adult
with sickle cell anemia and B. holmesii bacteremia. We also
compared this bacterium with various B. holmesii isolates and a
reference strain and with B. pertussis and B. bronchiseptica isolates.
Nothing is known about the bacterial determinants involved in
B. holmesii pathogenicity, whereas those expressed by B. pertussis
and B. bronchiseptica are well characterized. B. pertussis and B.
bronchiseptica are known to produce similar bacterial proteins
involved in pathogenicity. These proteins are classiﬁed as adhes-
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ins (e.g. ﬁlamentous hemagglutinin (FHA), agglutinogens such
as pertactin or PRN, and ﬁmbrial proteins such as FIM2 and
FIM3) and toxins such as pertussis toxin or PT, tracheael cyto-
toxin or TCT and adenylate cyclase–hemolysin or AC-Hly
[12–14]. All of these bacterial determinants are expressed by B.
pertussis and B. bronchiseptica except for PT, which is speciﬁc to
B. pertussis [12]. They induce and are involved in the synthesis
of antibodies during the disease [13,14]. The synthesis of these
toxins and adhesins depends on the environmental conditions
and the stage of the disease [13,14], and this variation results in
various phenotypes known as phases I, II, III and IV. One
of the major differences between phases I and IV, the best
characterized, is that phase I variants synthesize both adhesins
and toxins, whereas phase IV variants produce neither [14].
Environmental conditions such as temperature or the addition
of sulfate ions [15] may result in the transformation of phase I
variants into phase IV variants. This transformation is reversible
and is called phase modulation. Phase I variants may also be
transformed into phase IV variants by mutations in the genes
encoding the proteins of the two-component regulatory system
(bvg locus). Such transformation of phase I into phase IV is
rarely reversible and is called phase variation. Nothing is known
about the bacterial determinants involved in the pathogenicity
of B. holmesii, or the regulation of their expression. We used
sera from patients infected with B. pertussis, B. bronchiseptica and
B. holmesii [13, 16,17] to analyze and compare the proteins
produced by the B. holmesii isolate with those of a reference
strain and other isolates of B. holmesii and with phase variants
of B. pertussis and B. bronchiseptica.
MATERIALS AND METHODS
Case history
In September 1996, a 24-year-old patient native of Benin was
admitted into day hospital for a dry cough with ﬁts and fever
up to 39 °C. There was no dyspnea or thoracic pain. However,
he did complain of painful shoulders and elbows.
The patient’s medical history included a neonatal diagnosis
of sickle cell anemia, osteomyelitis of the right tibia leading to
surgery at the age of 6 years (frequent painful joints and abdomi-
nal crises occurred until the age of 8 years, necessitating multiple
transfusions), hepatitis C infection, a cholecystectomy for vesi-
cal lithiasis in 1993, and chronic priapism.
During hospitalization, the patient was well in spite of fever
up to 38.5 °C, and pain of the upper limbs. Blood pressure
was 148/82mmHg and pulse was 54/min. Moderate painless
hepatomegaly was detected, while the spleen was not palpable,
pain in the joints of the arms was not increased by palpation
and immobilization, chest X-rays were normal and the leu-
kocyte count was 13 700/mm3 (absolute neutrophil count of
9170). Hemoglobin concentration remained usual for the patient
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(7.7 g/dL), with a platelet count of 400 000/mm3. Three
hemocultures were performed at 2-h intervals, and B. holmesii
was isolated. The patient was hydrated and was given 2 g of
amoxicillin–clavulanate intravenously during his stay in day
hospital. He was discharged and told to take 2 g of amoxicillin–
clavulanate for 7 days. The evolutionwasmarked by incomplete
improvement. Three weeks later, the patient was readmitted
with fever (37.5–38.5 °C). Clinical examination remained
unchanged, with normal radiography and blood gases, and no
sign of infectious endocarditis. Blood cultures were negative.
Oral erythromycin (2 g daily for 4weeks) resulted in a complete
cure of the infection after 3 weeks. On follow-up, the patient
was found to be asymptomatic.
Bacterial isolation and identiﬁcation
Three hemocultures were set up at 2-h intervals. After 6 days
of growth at 37 °C, small colonies of a Gram-negative bac-
terium were detected. A 48-h subculture on Bordet Gengou
Agar supplemented with 15% deﬁbrinated blood (BGA, Difco,
Detroit, MI, USA) showed small, brilliant, non-hemolytic col-
onies about 1mm in diameter producing a brown pigment.
The bacterium isolated from the blood of the patient was
identiﬁed as B. holmesii on the basis of its bacteriologic charac-
teristics and comparison with other B. holmesii isolates. It was
non-oxidizing, strictly aerobic and non-motile. It tested nega-
tive for oxidase, urease, indole, citrate and nitrate, and positive
for catalase. It grew at 25 °C and 35 °C but not at 42 °C.
Antibiotic susceptibility testing
The disk diffusion technique was used to determine antibiotic
susceptibility, according to the guidelines of the ‘Comite´ de
l’Antibiogramme de la Socie´te´ Franc¸aise de Microbiologie’
[18]. Disk diffusion susceptibility tests involve measurement of
the diameter of the circle around the disk free of bacteria, which
is correlated with the MIC of the antibiotic. A regression curve
can be used to estimate theMIC. The bacteriumwas susceptible
to amoxycillin, amoxycillin plus clavulanic acid, cephazolin,
cefotaxime, gentamicin, tobramicin, amikacin, chloram-
phenicol, tetracycline, erythromycin, pristinamycin, peﬂox-
acin, rifampicin and co-trimoxazole, but resistant to penicillin
G and lincomycin.
Strains and bacterial suspensions
The Bordetella strains used in this study are listed in Table 1.
Bacterial suspensions were prepared from bacteria grown on
BGA for 24 h at 36 °C and resuspended in saline at 1.8× 1010
CFU/mL.
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Table 1 Strains used in this study
Strain or isolate Phase Origin Reference
B. pertussis 18323 (ATCC 9797) Phase I Human 1
B. pertussis 18323H− Phase IV Human 23
B. pertussis Tohama I Phase I Human 24
B. pertussis 359 Phase IV Human 24
B. bronchiseptica 9.73H+ Phase I Rabbit 13
B. bronchiseptica 9.73H– Phase IV Rabbit 13
B. bronchiseptica Rem1 Phase I Human 18
B. bronchiseptica Rem1H– Phase IV Human 18
B. holmesii ATCC 51541 ? Human 9
B. holmesii G7702 ? Human 9
B. holmesii G8341 ? Human 9
B. holmesii G8350 ? Human 9
B. holmesil 1 ? Human This study
Western blot analysis
Bacterial suspensions were diluted in Laemmli buffer [19], and
boiled for 15min. Bacterial proteins were detected by western
blotting with antibodies as previously described [20]. Brieﬂy,
SDS-polyacrylamide gel electrophoresis was performed using
ready-to-use 8–25% polyacrylamide gels with the Phast system
(Pharmacia, Uppsala, Sweden). The separated proteins were
transferred to Hybond C-super membranes (Amersham). The
membranes were blocked and incubated overnight at 4 °C with
a 1 in 2000 dilution of human serum or with various dilutions
of speciﬁc anti-FHA, anti-PT, anti-PRN or anti-AC-Hly sera.
Antibodies were detected with peroxidase-labeled antihuman
immunoglobulins and the Amersham enhanced chemi-
luminescence system [20].
Speciﬁc antitoxin and antiadhesin sera
AC-Hly, PT, PRN and FHA were detected in bacterial sus-
pensions by western blotting with speciﬁc polyclonal sera as
previously described [20]. Fimbria production was detected
by agglutination with monoclonal anti-FIM2 and anti-FIM3
antibodies [21].
Human sera
A pool of human sera was prepared by mixing sera from patients
infected with B. pertussis or B. bronchiseptica [13,16].
RESULTS
The bacterium isolated from the blood of our patient was
identiﬁed as B. holmesii by comparing its bacteriologic charac-
teristics with those of the B. holmesii reference strain.
Bacterial suspensions were prepared from this isolate, grown
on BGA, B. pertussis and B. bronchiseptica phase I and phase IV
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variants, the B. holmesii reference strain (ATCC 51541) and
three other B. holmesii isolates. We used western blotting with
polyclonal sera speciﬁc for puriﬁed FHA, PRN, PT and AC-
Hly, to analyze the proteins produced by the B. holmesii ref-
erence strain and isolates. Some of these proteins were detected
in phase I B. pertussis and B. bronchiseptica bacterial suspensions
(Table 2). As expected, no protein was detected in phase IV B.
pertussis and B. bronchiseptica bacterial suspensions and PT was
detected exclusively in phase I B. pertussis bacterial suspensions.
None of these proteins was detected in B. holmesii bacterial
suspensions (Table 2).
Agglutination and western blots with monoclonal anti-FIM2
and anti-FIM3 antibodies showed these proteins to be present
only in bacterial suspensions of phase I B. pertussis strains
(Table 2).
We then analyzed bacterial proteins detected with pools
of sera from patients infected with either B. pertussis or B.
bronchiseptica and compared them with those detected with the
serum of our patient, infected with B. holmesii. The pools of
sera from patients infected with B. pertussis or B. bronchiseptica
detected proteins in the various bacterial suspensions (Figure
1). Some proteins were speciﬁcally detected in phase I bacterial
suspensions of B. pertussis isolates, as expected; others were
detected in either phase I or phase IV, indicating that their
synthesis was not regulated by the two-component regulatory
system.
Unlike the pool of sera from B. pertussis-infected patients,
which detected only one protein in B. holmesii bacterial sus-
pensions, the pool of sera from B. bronchiseptica-infected patients
detected several proteins in all B. holmesii bacterial suspensions
(Figure 1). However, this serum did not detect the same pro-
teins in all bacterial suspensions. Two high-molecular-weight
proteins were detected by this serum in only two B. holmesii
bacterial suspensions (Bh G8341 and Bh no. 1), these proteins
were not detected in the others (Bh G7702 and ATCC 51541).
The serum of the patient infected with B. holmesii detected
proteins in all bacterial suspensions but none of the proteins
speciﬁc to phase I B. pertussis and phase I B. bronchiseptica. The
proteins detected in the four B. holmesii bacterial suspensions
were also not identical. High-molecular-weight proteins were
detected in two B. holmesii bacterial suspensions (BhG8341 and
Bh no.1) but not in the others (Figure 1). The proteins detected
by the serum from theB. holmesii-infected patient were identical
to those detected by the pooled sera from B. bronchiseptica-
infected patients. The proteins detected in the bacterial sus-
pension of B. holmesii G8350 by the various sera were similar
to those detected in bacterial suspensions of B. holmesii ATCC
51541 and B. holmesii G7702 (data not shown).
We investigated whether the synthesis of these two proteins
was affected by temperature or sulfate ions, by growing the B.
holmesii reference strain and isolates at 25 °C and 37 °C. The
synthesis of these high-molecular-weight proteins, as detected
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Table 2 Detection of B. pertussis toxins and adhesins
Strain or isolate FHA PRN Fim2 Fim3 PT AC-Hly
B. pertussis 18323 + + + + + +
B. pertussis 18323H– – – – – – –
B. pertussis Tohama 1 + + + – + +
B. pertussis 359 – – – – – –
B. bronchiseptica 9.73H+ + + – – – +
B. bronchiseptica 9.73H– – – – – – –
B. bronchiseptica Rem1 + + – – – +
B. bronchiseptica Rem1H– – – – – – –
B. holmesii ATCC 51541 – – – – – –
B. holmesii G7702 – – – – – –
B. holmesii G8341 – – – – – –
B. holmesii G8350 – – – – – –
B. holmesil 1 – – – – – –
Figure 1 One microliter of bacterial suspension (1.8×1010 CFU/mL) was loaded onto a gel and subjected to electrophoresis. The proteins
were transferred to a nitrocellulose membrane which was incubated in human serum as described in Materials and Methods. Suspensions
of B. pertussis Tohama phase I, B. pertussis 359 phase IV, B. bronchiseptica Rem 1 phase I, B. bronchiseptica Rem 1 phase IV, B. holmesii 1,
B. holmesii ATCC 51541, B. holmesii G7702 and B. holmesii G8341 were used. The sera used comprised a pool of sera from B. pertussis-
infected patients (A), a pool of sera from B. bronchiseptica-infected patients (B) and serum from a B. holmesii 1-infected patient (C).
by a pool of sera from B. bronchiseptica-infected patients or
serum from a B. holmesii-infected patient, was not regulated by
temperature (Figure 2). The synthesis of these proteins was also
unaffected by the addition of magnesium sulfate to the growth
medium (data not shown).
DISCUSSION
We isolated a B. holmesii-like bacillus from a patient with sickle
cell anemia. B. holmesii, originally called ‘CDC non-oxidizer
group 2’, has been recovered from blood cultures, mostly from
young adults and recently from sputum carried in the oral-
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/respiratory tract of humans and animals [10]. However, the
normal habitat of B. holmesii is unclear.
The bacillus identiﬁed in this study was isolated from a young
adult with sickle cell anemia and possessed all the biochemical
characteristics of previously reported B. holmesii isolates [9–
11]. It was susceptible to most antibiotics used to treat Gram-
negative bacillus infections. Our results suggest that ampic-
illin/sulbactam treatment followed by macrolides gives a fav-
orable clinical outcome, even in a patient with invasive
infections as described in this study.
As nothing is known about the bacterial determinants
involved in B. holmesii pathogenicity, we analyzed the
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Figure 2 One microliter of bacterial suspension (1.8×1010 CFU/mL)
was loaded onto a gel and subjected to electrophoresis. The proteins
were transferred to a nitrocellulosemembrane which was incubated
in human serum as described in Materials and Methods. Sus-
pensions of B. holmesii 1 grown at 37 °C, B. holmesii 1 grown at
25 °C, B. holmesii ATCC 51541 grown at 37 °C and B. holmesii ATCC
51541 grown at 25 °C were used. Similar results were obtained for
B. holmesii 1 andB. holmesiiG8341, and forB. holmesiiATCC 51541,
B. holmesii G7702 and B. holmesii G8350. (A) Pool of sera from B.
bronchiseptica-infected patients. (B) Pool of sera from B. holmesii-
infected patients.
B. holmesii isolate collected in this study and compared it with
other B. holmesii isolates, a reference strain and B. pertussis
and B. bronchiseptica phase I and IV strains. B. pertussis and B.
bronchiseptica exhibit different phenotype phases according to
the environmental conditions or stage of the disease [14]. One
of the differences between phases I and IV concerns the syn-
thesis of the toxins and adhesins involved in the disease. Phase
I bacteria synthesize adhesins and toxins such as FHA, PRN,
FIM 2 and -3, PT and AC-Hly, which induce the synthesis of
antibodies during the disease and are virulent in animal models,
whereas phase IV bacteria do not produce these toxins and
adhesins and are avirulent in animal models [14]. We ﬁrst tried
to detect these toxins and adhesins using speciﬁc poly- or
monoclonal antibodies. None were detected in B. holmesii bac-
terial suspensions, suggesting that these proteins are either not
produced by B. holmesii or that the proteins produced do not
cross-react with those expressed by B. pertussis and B. bron-
chiseptica. Further experiments, such as DNA hybridization, are
necessary to verify the absence of structural genes encoding
toxins and adhesins on the B. holmesii chromosome.
Using pools of sera from patients infected with B. pertussis or
B. bronchiseptica, we conﬁrmed the speciﬁc detection of some
phase I-speciﬁc proteins in bacterial suspensions from phase I
B. pertussis or B. bronchiseptica but not in bacterial suspensions
from phase IV variants. The serum of the B. holmesii patient
(who was not vaccinated against whooping cough and had no
record of having had the disease) detected some proteins in
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B. pertussis and B. bronchiseptica bacterial suspensions. These
proteins were not speciﬁc to either phase I or IV. Some proteins
detected in B. holmesii bacterial suspensions using the serum of
the B. holmesii-infected patient were similar to proteins detected
by pools of sera from patients infected with B. pertussis or B.
bronchiseptica, suggesting cross-reactions between the proteins
produced by the various Bordetella species. Unexpectedly, the
proteins detected in the ﬁve B. holmesii bacterial suspensions by
the serum of the B. holmesii-infected patient were not similar.
Some bacterial proteins were detected in all ﬁve bacterial sus-
pensions, but others, including at least two high-molecular-
weight proteins, were detected only in the bacterial suspensions
from B. holmesii isolate G8341 and from the isolate collected in
this study but not in the bacterial suspensions of the other two
B. holmesii isolates (BhG7702 and Bh G8350) and the reference
strain (ATCC 51541). Thus, different proteins are produced by
these ﬁve B. holmesii strains. Thus, either the members of the
CDC non-oxidizer group differ from one another or B. holmesii
like B. pertussis and B. bronchiseptica may have different phases.
The B. holmesii isolates may have been stored in different phases
depending on how they were collected and the stage of the
disease. Environmental conditions such as temperature, or nic-
otinic acid levels and the addition of sulfate groups may affect
the synthesis of toxins and adhesins by B. pertussis and B. bron-
chiseptica. However, we found that the amount of these high-
molecular-weight proteins was not affected by growing B.
holmesii at a different temperature or in the presence of mag-
nesium sulfate. It is also possible that the genes encoding these
proteins are carried by a plasmid. However, we detected no
plasmids in any of the B. holmesii isolates studied (data not
shown).
Unexpectedly, the pool of sera from B. pertussis-infected
children did not detect these proteins, whereas the pool of sera
from B. bronchiseptica-infected patients did. This suggests that
B. bronchiseptica is more similar to B. holmesii than to B. pertussis
in terms of the proteins produced. However, 16S rRNA data
indicate that B. holmesii is more closely related to B. pertussis
[9].
In conclusion, we identiﬁed a B. holmesii bacillus that is very
similar to the CDC B. holmesii reference strain (ATCC 51541)
in its bacteriologic characteristics and produces similar proteins
as detected by the serum of the B. holmesii-infected patient.
However, experiments with sera from patients infected with B.
pertussis, B. bronchiseptica or B. holmesii showed that (1) these
three species have some proteins in common but also produce
some species-speciﬁc proteins, and (2) the proteins produced by
the B. holmesii isolates analyzed in this study are phenotypically
diverse. Further studies are required to determine whether this
is due to phase variation in B. holmesii, to the presence of
proteins speciﬁcally produced at a particular stage of the disease,
or to the presence of a plasmid harbored by some strains and
not by others.
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